Please use this identifier to cite or link to this item:
https://doi.org/10.18632/oncotarget.17633
DC Field | Value | |
---|---|---|
dc.title | Human mesenchymal stem cells preferentially migrate toward highly oncogenic human hepatocellular carcinoma cells with activated EpCAM signaling | |
dc.contributor.author | Endaya B | |
dc.contributor.author | Guan S.P. | |
dc.contributor.author | Newman J.P. | |
dc.contributor.author | Huynh H. | |
dc.contributor.author | Sia K.C. | |
dc.contributor.author | Chong S.T. | |
dc.contributor.author | Kok C.Y.L. | |
dc.contributor.author | Chung A.Y.F. | |
dc.contributor.author | Liu B.B. | |
dc.contributor.author | Hui K.M. | |
dc.contributor.author | Lam P.Y.P. | |
dc.date.accessioned | 2020-09-09T01:19:11Z | |
dc.date.available | 2020-09-09T01:19:11Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Endaya B, Guan S.P., Newman J.P., Huynh H., Sia K.C., Chong S.T., Kok C.Y.L., Chung A.Y.F., Liu B.B., Hui K.M., Lam P.Y.P. (2017). Human mesenchymal stem cells preferentially migrate toward highly oncogenic human hepatocellular carcinoma cells with activated EpCAM signaling. Oncotarget 8 (33) : 54629-54639. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.17633 | |
dc.identifier.issn | 19492553 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/174894 | |
dc.description.abstract | The epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein that is regarded as one of the markers for tumor initiating cells (TIC) in human hepatocellular carcinoma (HCC). Much work has been directed towards targeting these TICs as a mean of placing these master regulators of cell proliferation and drug resistance under control. Human bone marrow-derived mesenchymal stem cells are known to exhibit an innate property of tumor tropism. However, the possible relationship between MSC and TIC is not well understood. In this study, we show that MSC migration to HCC can be effectively inhibited by TACE and ?-secretase inhibitors that stop the activation of EpCAM signaling event. Silencing of EpCAM expression through siRNA and antibody approaches also resulted in impaired MSC migration. By contrast, increase levels of EpICD proteins in HCC cells and HCC mouse xenografts resulted in enhanced MSC migration. Taken together, these findings show that MSC is drawn to the more oncogenic population of HCC, and could potentially serve as a cell-based carrier of therapeutic genes to target EpICD-enriched hepatic tumor cells. © Endaya et al. | |
dc.publisher | Impact Journals LLC | |
dc.source | Unpaywall 20200831 | |
dc.subject | epithelial cell adhesion molecule | |
dc.subject | gamma secretase inhibitor | |
dc.subject | small interfering RNA | |
dc.subject | tumor necrosis factor alpha converting enzyme inhibitor | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | Article | |
dc.subject | cell migration | |
dc.subject | controlled study | |
dc.subject | embryo | |
dc.subject | hepatocellular carcinoma cell line | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | human tissue | |
dc.subject | liver carcinogenesis | |
dc.subject | liver cell carcinoma | |
dc.subject | mesenchymal stem cell | |
dc.subject | mouse | |
dc.subject | nonhuman | |
dc.subject | protein expression | |
dc.subject | signal transduction | |
dc.subject | tumor xenograft | |
dc.type | Article | |
dc.contributor.department | BIOCHEMISTRY | |
dc.contributor.department | PHARMACOLOGY | |
dc.contributor.department | PHYSIOLOGY | |
dc.description.doi | 10.18632/oncotarget.17633 | |
dc.description.sourcetitle | Oncotarget | |
dc.description.volume | 8 | |
dc.description.issue | 33 | |
dc.description.page | 54629-54639 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_18632_oncotarget_17633.pdf | 4.82 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.